Pharmacological body-wide and immunotropic effects of galavit in the treatment of patients with purulent-inflammatory diseases of various origins and allergization

Authors

DOI:

https://doi.org/10.18413/rrpharmacology.9.10044

Abstract

Introduction: Patients with purulent-inflammatory diseases (PID), especially those with allergization, manifest chronicity, low treatment efficiency, and the risk of relapses; the above actualizes the search for innovative treatment technologies.

The aim of the study: The aim of the study was to specify pharmacological (body-wide) and specific (immunotropic) effects of the immunomodulator galavit additionally prescribed in the context of basic treatment for patients with deep pyoderma, chronic pyelonephritis, adnexitis, purulent infection of soft tissues, complicated by atopic dermatitis.

Materials and Methods: The study included 331 patients with PID and 30 healthy volunteers of the same age and gender who were examined prior and following the basic treatment of each nosoform. The diverse clinical and laboratory examination options were applied to investigate 17 clinical, 7 hematological, 16 immunological, 13 metabolic parameters that were grouped into clinical, hematological, immunological and metabolic syndromes, and divided into links – cellular, humoral, phagocytic, cytokine, metabolic and antioxidant. The results were statistically processed using variational parametric and nonparametric techniques; this allowed calculating the coefficient of diagnostic value, diagnostic formulas of disorders and targets of galavit under various conditions.

Results and Discussion: Targeted pharmacological therapy with galavit reliably eliminates clinical, hemato-immuno-metabolic disorders in patients with PID, though dependently on the nosoform of the disease.

Conclusion: It was demonstrated that the correction of clinical and laboratory disorders depend on PID pathogenesis and allergization; the laboratory mechanism of therapeutic effects was specified.

Graphical Abstract

Keywords:

atopic dermatitis, galavit, purulent-inflammatory diseases, immuno-metabolic disorders, clinical and laboratory efficiency

References

Berezhnova TA, Dyadina KS, Kulintsova YV (2020) Immune-metabolic therapy of purulent inflammatory diseases. Research Results in Pharmacology. 6(4): 1–6. https://doi.org/10.3897/rrpharmacology.6.55628

Bhargava P, Fitzgerald KC, CalabresiPA, Mowry EM (2017) Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation The Journal of Clinical Ivestigation 2(19): e95302. https://doi.org/10.1172/jci.insight.95302 [PubMed]

Bollestad M, Vik I, Grude N, Lindbæk M (2018) Predictors of symp­tom duration and bacteriuria in uncomplicated urinary tract infec­tion. Scandinavian Journal of Primary Health Care 36(4): 446–454. https://doi.org/10.1080/02813432.2018.1499602 [PubMed] [PMC]

Bratchikov OI, Tyuzikov IA, Dubonos PA (2020) Clinical and experimental rationale for antioxidant therapy of chronic bacterial prostatitis. Research Results in Pharmacology 6(1): 11–19.https://doi.org/10.3897/rrpharmacology.6.50940 [in Russian]

Calogero AE, Condorelli RA, Vignera SL (2017). Antioxidants in male accessory gland infection. In: Balercia G, Gandini L, Lenzi A, Lombardo F (eds) Antioxidants in Andrology. Trends in Andrology and Sexual Medicine. Springer, Cham, pp. 59–69. https://doi.org/10.1007/978-3-319-41749-3_5

Daniels AM, Schulte AR, Herndon CM (2018) Interstitial cystitis: an update on the disease process and treatment. Journal of Pain and Palliative Care Pharmacotherapy 32(1): 49–58. https://doi.org/10.1080/15360288.2018.1476433[PubMed]

Dellis AE, Papatsoris AG (2018) Bridging pharmacotherapy and min­imally invasive surgery in interstitial cystitis/bladder pain syndrome treatment. Expert Opinion on Pharmacotherapy 19(12): 1369–1373. https://doi.org/10.1080/14656566.2018.1505865 [PubMed]

Desai MK, Brinton RD (2019) Autoimmune disease in women: endocrine transition and risk across the lifespan. Frontiers in En­docrinology 10: 265. https://doi.org/10.3389/fendo.2019.00265 [PubMed] [PMC]

Ditkoff EL, Theofanides M, Aisen CM, Kowalik CG, Cohn JA, Sui W, Rutman M, Adam RA, Dmochowski RR, Cooper KL (2018) Assessment of practices in screening and treating women with bacteriuria. The Canadian Journal of Urology 25(5): 9486–9496. [PubMed]

Falconi-McCahill A (2019) Bacterial vaginosis: A clinical update with a focus on complementary and alternative therapies. Journal of Midwifery and Women’s Health 64(5): 578–591. https://doi.org/10.1111/jmwh.13013 [PubMed]

Faught BM, Reyes S (2019) Characterization and treatment of recurrent bacterial vaginosis. Journal of Women’s Health 28(9): 1218–1226. https://doi.org/10.1089/jwh.2018.7383 [PubMed]

Forti P, Pirazzoli GL, Maltoni B, Bianchi G, Magalotti D, Muscari A (2019) Metabolic syndrome and all-cause mortality in older men and women. European Journal of Clinical Investigation 42(9): 1000–1009. https://doi.org/10.1111/j.1365-2362.2012.02688.x [PubMed]

Genest J (2017) Familial hypercholesterolemia: awareness, appraisal, and action. The Canadian Journal of Cardiology 33(3): 298–299. https://doi.org/10.1016/j.cjca.2016.09.011 [PubMed]

Germano N, Sibbel MG, Summerfield D, Pitzenberger A (2019) Group B streptococcus meningitis complicated by periodic lateralis­ingepileptiform discharges in an elderly patient with type 2 diabetes mellitus. BMJ Case Reports 12(8): e228040. https://doi.org/10.1136/bcr-2018-228040 [PubMed] [PMC]

Goktas O, Ersoy C, Ercan I, Can FE (2019) General and abdomi­nal obesity prevelances and their relations with metabolic syndrome components. Pakistan Journal of Medical Sciences 35(4): 945–950. https://doi/org/10.12669/pjms.35.4.235 [PubMed] [PMC]

Huang X, Lu T, Guo Z, Wei L, Chen S, Qiu W, Lu Z (2019) Susceptibility-weighted imaging in the differential diagnosis of autoimmune central nervous system vasculitis and multiple sclerosis. Multiple Sclerosis and Related Disorders 33: 70–74. https://doi.org/10.1016/j.msard.2019.05.012 [PubMed]

Jung YS, Park JH, Park DI, Sohn CI, Lee JM, Kim TI (2018) Physical inactivity and unhealthy metabolic status are associated with decreased natural killer cell activity. Yonsei Medical Journal 59(4): 554–562. https://doi.org/10.3349/ymj.2018.59.4.554 [PubMed] [PMC]

Keagy CD (2018) The potential role of folate metabolism in interstitial cystitis. International Urogynecology Journal 29(10): 1379–1385. https://doi.org/10.1007/s00192-018-3771-7 [PubMed]

Pokrovskaya LA, Zubareva EV, Nadezhdin SV, Lysenko AS, Litovkina TL (2020) Biological activity of mesenchymal stem cells secretome as a basis for cell-free therapeutic approach. Research Results in Pharmacology 6(1): 57–68. https://doi.org/10.3897/rrpharmacology.6.49413 [in Russian]

Tokmakov AI (2009) The use of combined immunocorrection in the complex treatment of purulent wounds of soft tissues. PhD thesis, Burdenko Voronezh State Medical Academy, Voronezh, Russia. [in Russian]

Zemskov AM, Zemskov VM, Chereshnev VA (2013) Immunology. Drug reference of immunotropic drugs and effects. Volume 2. Triada-X Publishing House, Moscow, 403 p. [in Russian]

Zemskov AM, Berezhnova TA, Zemskova VA, Dyadina KS, Kulintsova YV, Larin AV (2019) Immune-metabolic genesis of pathological processes. Research Results in Pharmacology 5(4): 19–31. https://doi.org/10.3897/rrpharmacology.5.38386 [in Russian]

Zhang T, De Carolis C, Man GCW, Wang CC (2018) The link between immunity, autoimmunity and endometriosis: a litera­ture update. Autoimmunity Reviews 17(10): 945–955. https://doi.org/10.1016/j.autrev.2018.03.017 [PubMed]

Author Contribution

Veronika A. Zemskova, N.N. Burdenko Voronezh State Medical University

Candidate of Sciences (in Medicine), Associate Professor of the Department of Pathophysiology, N.N. Burdenko Voronezh State Medical University; e-mail: patfiz@vsmaburdenko.ru; ORCID ID http://orcid.org/0000-0002-0004-1406. Author’s contribution: analysis and interpretation of the research results; preparation and editing of the text of the manuscript; scientific design.

Yuliya A. Trubchanina, N.N. Burdenko Voronezh State Medical University

Assistant of the Department of Pharmacology, Burdenko Voronezh State Medical University; e-mail: kaldina.96@mail.ru; ORCID ID http://orcid.org/0000-0003-1738-7523. Author’s contribution: collection, analysis and interpretation of the obtained data; preparation and drafting the manuscript.

Tatyana A. Berezhnova, N.N. Burdenko Voronezh State Medical University

Doctor Habilit. of Medicine, Professor, Dean of the Faculty of Pharmacy, Head of the Department of Pharmacology, N.N. Burdenko Voronezh State Medical University, Voronezh, Russia; e-mail: berezhnova-tatjana@rambler.ru; ORCID ID https://orcid.org/0000-0002-8401-3460. Author’s contribution: development of the concept – conceptualization and development of the research direction; formulation of key goals and objectives.

Andrey M. Zemskov, N.N. Burdenko Voronezh State Medical University

Doctor Habilit. of Medicine, Professor, Head of the Department of Microbiology, NN Burdenko Voronezh State Medical University,Voronezh, Russia; e-mail: microbiologvgma@yandex.ru; ORCID ID http://orcid.org/0000-0002-7056-5934. Author’s contribution: development of the concept – conceptualization and development of the research direction; formulation of key goals and objectives.

Vladimir A. Borisov, N.N. Burdenko Voronezh State Medical University

Candidate of Sciences (in Medicine), Associate Professor of the Department of Pharmacology, N.N. Burdenko Voronezh State Medical University, Voronezh, Russia; e-mail: borisov_2002@mail.ru; ORCID ID https://orcid.org/0000-0002-6175-7336. Author’s contribution: critical revision of the manuscript with offering valuable comments.

Nadezhda Yu. Kuzmenko, N.N. Burdenko Voronezh State Medical University

Candidate of Sciences (in Medicine), Associate Professor of the Department of Pharmacology, N.N. Burdenko Voronezh State Medical University, Voronezh, Russia; e-mail: nadezhda.kuzm@mail.ru; ORCID ID https://orcid.org/0000-0001-7922-8814. Author’s contribution: critical revision of the manuscript with offering valuable comments.

Kseniya S. Dyadina, N.N. Burdenko Voronezh State Medical University

Candidate of Sciences (in Medicine) Associate Professor of the Department of Pharmaсology, N.N. Burdenko Voronezh State Medical University, Voronezh, Russia; e-mail: dyadina_2017@mail.ru; ORCID ID https://orcid.org/0000-0003-2454-729X. Author’s contribution: critical revision of the manuscript with offering valuable comments.

Downloads

Published

30-09-2023

How to Cite

Zemskova VA, Trubchanina YA, Berezhnova TA, Zemskov AM, Borisov VA, Kuzmenko NY, Dyadina KS (2023) Pharmacological body-wide and immunotropic effects of galavit in the treatment of patients with purulent-inflammatory diseases of various origins and allergization. Research Results in Pharmacology 9(3): 41–49. https://doi.org/10.18413/rrpharmacology.9.10044

Issue

Vol. 9 No. 3 (2023)

Section

Clinical Pharmacology

License

Copyright (c) 2023 Вероника А. Земскова, Юлия А. Трубчанина, Татьяна А. Бережнова, Андрей М. Земсков, Владимир А. Борисов, Надежда Ю. Кузьменко, Ксения С. Дядина

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)